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Abstract
Background: Proper adherence to isoniazid preventive therapy (IPT) may depend upon the results of tuberculosis
(TB) screening test and patients’ understanding of their risk of developing active TB. We conducted a study to
assess the acceptability, adherence and completion profile of IPT among HIV-infected patients who were clinically
screened for latent TB Infection (LTBI).
Methods: A multicenter observational study was conducted in Dar es Salaam, Tanzania between February 2012
and March 2014. HIV-infected patients 10 years or older were clinically screened using a validated symptom-based
screening tool to rule out active TB. Patients found to have no symptoms in the screening tool were given 300 mg
of isoniazid (INH) daily for 6 months. Patients were followed up monthly at the National and Municipal hospital HIV
clinics for INH refill and assessment of treatment adherence. Adherence was defined as consumption of 90 % or
more of the monthly prescription of INH.
Results: All 1303 invited patients agreed to participate in the study. Of 1303 invited HIV-infected patients, 1283
(98.5 %) were recruited into the study. Twenty eight (2.2 %) did not complete treatment. Those who did not
complete the treatment were exclusively adults aged 18 years or older, p = 0.302. The overall mean (±SD) adherence
was 98.9 % (±2.9). Adherence level among children aged <18 years (92.2 %) was significantly lower than adherence
level among patients aged 18–29 years (98.3 %), 30–49 years (98.8 %) and ≥ 50 years (98.5), p-value = 0.011. Sex,
occupation, socio-economic status, duration of HIV infection, being on antiretroviral drugs (ARV) and duration of
ARV use were not associated with adherence.
Conclusion: IPT is highly accepted by HIV infected patients. Patients demonstrated high level of adherence to
IPT. The level of adherence among children was slightly lower than that among adults. IPT non-completers were
exclusively adults. Children might need adult supervision in taking IPT.
Introduction
Tanzania is one of the 22 high burden countries (HBC)
for tuberculosis (TB) according to the World Health
Organization (WHO) [1] This TB epidemic is largely
fueled by co-infection with human immunodeficiency
virus (HIV). In 2011 the WHO recommended that pa-
tients infected by HIV in resource constrained settings
should receive isoniazid preventive therapy (IPT) to reduce
the incidence of TB [2]. IPT consists of isoniazid (INH)
300 mg. administered orally on a daily basis for
6 months. The recommendation is based on the evi-
dence that IPT is both efficacious [3, 4] and relatively in-
expensive [2, 5]. Despite the available evidence that IPT
is efficacious many countries have failed to implement
this recommendation. Concerns about IPT adherence, the
cost of ruling out active TB, the safety of the long term
use of INH and fear of the emergence of resistance to
INH have all been cited as reasons for this failure [2].
Other countries have embraced it with Botswana
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having the largest number of HIV infected patients on
IPT in the world [2].
Research on IPT provision has revealed variable rates
of acceptance and completion of TB preventive therapy
among populations at risk for TB. The overall completion
rate for IPT was only 45 % in a 2010 study among patients
attending chest clinics in New York City [6]. Alternatively,
the IPT completion rate among HIV infected patients with
a positive tuberculin skin test (TST) who received coun-
seling and transport reimbursement was 87 % in a 2008
study in Dar es Salaam, Tanzania [7]. Adherence to IPT
in TST-positive and non-TST-screened HIV infected
subjects in Thailand in 2004 was 84.5 and 79.7 % by
self- reporting, and 81.8 and 73.9 % by pill count monitor-
ing [8]. In 2014 Berhe et al., reported an IPT adherence
rate of 86.5 % at one month among HIV infected patients
in Ethiopia [9].
Good adherence to IPT has been linked to counseling
before initiation of therapy, freedom to take INH publicly,
and regular attendance at follow-up clinics [10]. Other
relevant factors shown to affect IPT adherence in HIV
infected patients include understanding of IPT rationale,
beliefs about INH safety and concerns about potential INH
side effects. Additionally, patient denial of HIV infection,
HIV related stigma and concerns regarding concurrent use
of highly active anti-retroviral therapy (HAART) are also
relevant [11, 12]. Directly observed preventive therapy and
a shorter duration regimen for preventive therapy have
both been found to improve treatment completion rates
[4]. Barriers to implementation of IPT have been found to
be related to both patients’ factors as narrated above and
health care system factors [13]. A 2012 study in Uganda re-
ported a very low IPT completion rate at 33.6 % among
HIV infected patients in a non-governmental facility. Fac-
tors reported to have been associated with non-completion
included an age of less than 30 years and prior divorce,
separation or widowhood [14].
We conducted the present study to assess acceptability,
adherence and completion profile of IPT among HIV
infected patients who were clinically screened for LTBI
in Dar es Salaam, Tanzania.
Methods
Study design, site and population
This study was a prospective, observational multicenter
study conducted at four clinics providing HIV-AIDS treat-
ment services in Dar es Salaam. The study was conducted
between February 2012 and March 2014. Patients being
treated at these facilities were the study subjects. We
conducted this present study to assess patient acceptance,
adherence and completion profiles for IPT in HIV infected
patients aged 10 years or older. Study participants included
both those who had never treated with anti-retroviral
(ARV) drugs and those either previously or currently
being treated with ARV drugs.
All four HIV clinics are under the direction of the
National AIDS Control Program (NACP) of Tanzania.
All HIV-AIDS related treatment protocols and policies for
Tanzania are directed and coordinated by the NACP. HIV
treatment failures are managed at a higher-level referral
clinic in Dar es Salaam that was not included in this study.
Although the clinics in the study are sited at four different
facilities within Dar es Salaam they function identically.
All the clinics were urban set and were located at Muhim-
bili National Hospital (MNH) [a tertiary referral hospital
which is also a teaching hospital for the Muhimbili Uni-
versity of Health and Allied Sciences], Amana and Temeke
Municipal Hospitals which are secondary level hospitals
that refer cases to MNH and the Pastoral Activities and
Services for People with AIDS in Dar es Salaam Archdio-
cese (PASADA) Health Center. These HIV clinics operate
five days a week and each sees approximately seventy to
one hundred patients daily. All HIV infected patients are
routinely seen monthly for clinical evaluation and receive
refills of ARV drugs at the time of their visit.
The clinics at MNH, Amana, Temeke and PASADA
were among the fourteen centers participating in a separate
pilot study of IPT in HIV positive patients in Tanzania.
Data collection and procedures
Eligible patients were HIV infected outpatients, ARV
naïve or experienced, who were willing to stay in Dar es
Salaam for at least 2 years and were aged 10 years or older.
Trained nurses and doctors informed clinic patients about
the present study that was to go hand in hand with the na-
tional IPT pilot study and invited them to participate in the
study. Informed consent was obtained. Exclusion criteria
were known alcohol abuse, a current or past history of
hepatitis or other medical contraindications to INH ther-
apy. Additional exclusion criteria were current or recent
(within the past two years) TB treatment, active pregnancy,
a history of treatment non-compliance or the presence of
WHO clinical stage 4 AIDS [15].
Those who agreed to participate were screened to rule
out active TB using the National Tuberculosis and
Leprosy Program (NTLP) symptom-based screening
tool [16]. The tool is comprised of 5 questions asking for
the presence of cough for ≥ 2 weeks, fever for ≥2 weeks,
hemoptysis of any duration, excessive night sweats for ≥
2 weeks and noticeable weight loss or weight loss of ≥ 3 kg
within 4 weeks. We previously demonstrated the tool had
a sensitivity and specificity for identifying active TB of 71.4
and 75.9 % respectively in a HIV positive population being
considered for IPT for LTBI. The positive and negative
predictive values of the screening tool were 11.4 and
98.4 % respectively, with a false negative rate of 28.6 % [17].
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Patients who presented with any of the symptoms in
the screening tool were designated as being active TB
suspects and underwent standard TB screening. Those
confirmed with active TB were treated as per National
TB guidelines [15]. Patients with no confirmed TB were
eligible to be enrolled in the study. Patients who presented
with none of the symptoms in the tool were considered
to not have active TB and were assessed for IPT eligibility
as above.
Eligible patients were consecutively enrolled into the
study and initiated on IPT. The IPT comprised of INH
300 mg administered orally daily for 6 months in a non-
supervised fashion. Patients were provided with a monthly
dose of 30 tablets of INH to take home. Patients’ remaining
pills were counted to ascertain adherence at each monthly
follow up visit. A structured questionnaire was used to
collect demographic, socioeconomic and clinical data at
enrollment.
At each of the monthly visits the TB screening survey
tool was repeated to identify those who could have possibly
developed active TB during the follow up period. An inter-
val clinical history was collected at each follow up visit to
identify any new clinical developments or drug side effects.
A thorough monthly examination of the respiratory system,
lymphatic system, skin and mucous membranes, gastro-
intestinal tract (GIT), cardiovascular, central nervous
system and musculoskeletal systems for any concurrent
illness was conducted at each follow up visit.
Weight and body temperature were monitored in each
visit. Weight was measured using an analogue scale (SECA)
without shoes and was recorded to the nearest 0.5 kg.
Temperature was measured in degrees Celsius using a
digital thermometer.
Definition of terms
Adherence was defined as consumption of 90 % or more
of the monthly prescription of INH. IPT completion was
defined as having received and consumed Isoniazid for a
total of 6 months. Consent withdrawal meant a reported
participant’s voluntary cessation of both IPT use and
study participation. Lost to follow up was defined as ab-
sence from the clinic for at least two consecutive scheduled
visits and efforts to track the patients were in vain.
Ethical issues
Ethical clearance for the study was obtained from the
MUHAS Institutional Review Board (Reference number
MU/DRP/AEC/Vol.XVI/135). All the involved health
facilities gave permission for the study to be conducted in
the facilities. All patients consented to participate through
a written informed consent. Patients aged < 18 years
had their parents/guardians signed informed consent
on their behalf having themselves provided verbal assent.
Patients who screened positive to the screening tool were
fully worked up to diagnose or rule out active TB. Upon
diagnosis of active TB, patients were started on a full
course of anti-TB treatment as per Tanzania guidelines
[15]. All the data were handled with high confidentiality.
Statistical analysis
Data analysis was performed using SPSS version 20. Pro-
portions were used to describe the socio-demographics
of patients. Adherence to IPT was calculated for each
month using the pill count method. Tablets remaining in
a particular month were subtracted from 30 (the tablets
patients were given to carry home in each month). The
difference of the two was then divided by 30 before be-
ing multiplied by 100 to obtain percentage adherence.
The average of the adherence in the months the patients
were on treatment was calculated for each patient. This
is the parameter used in this study to describe adherence
to IPT. Therefore if a patient stayed in the study for only
2 months, his adherence was the average adherence of
the 2 months. Consumption of ≥ 90 % of monthly tablets
was considered good adherence.
Socioeconomic status of respondents was assessed by
the use of the factor analysis method [18]. A total of 16
variables were used to assess SES after being given
weights. These variables included the following items: 1)
family income per month; 2) type of the house walls (mud,
bricks, blocks etc.); 3) roofing material used (grass, iron
sheets, roof tiles etc.); 4) size of the house in terms of
number of the people sleeping in a room; 5) floor type
(mud, cement, wood, floor tiles etc.; 6) presence or ab-
sence of house ownership; 7) presence of electricity; 8)
presence of tap water; 9) toilet type (pit latrine, Asian
or European toilet etc.); 10) type of cooking fuel used
(charcoal, fire wood, electricity, cooking gas, etc.); 11)
car ownership; 12) television ownership; 13) refrigerator
ownership; 14) bicycle or motorcycle ownership; 15) radio
ownership; 16) fan ownership.
Non categorical variables had their means, frequencies
and standard deviations calculated. Variables with low
standard deviation were given a low weight as they had a
minimal ability to differentiate SES of the patients. Vari-
ables with high standard deviation were given a high
weight. The non-categorical variables were converted into
binary variables and weighted. A Principal Component
Analysis (PCA) was then used to derive factor scores for
every weighted variable using data reduction and regres-
sion method [18]. Variables that had a positive factor score
were associated with a high socioeconomic status while
those with a negative factor score were associated with a
low socioeconomic status. These factor scores were ana-
lyzed to generate the 3 categories of socioeconomic status.
Cross tabulations and Pearson’s Chi-square test were used
to obtain the associations and strength of relationship
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between the independent and the dependent variables.
Chi square test was used to compare adherence to IPT
across different socio-demographic and clinical charac-
teristics. P value of < 0.05 was considered significant.
Results
A total of 1303 patients were consecutively invited to
participate in the study. All 1303 (100 %) patients ac-
cepted to participate. Of the 1303 patients, 20 patients
were ineligible for the study due to alcohol abuse in 1
patient, 1 patient could not stay in the city for the study
duration, 7 patients were already on IPT, 7 patients were
either on TB treatment or had finished TB treatment
within 2 years, 3 patients had known liver disease and 1 pa-
tient had stage 4 HIV disease. A total of 1283 (98.5 %) were
eligible for the study and were offered IPT. At the end of
6 months of IPT 1255 patients had successfully completed
6 months of treatment. Non-completers numbered 28.
Reasons for non-completion of IPT were as follows: 2
withdrawals of consent (these withdrew from the study
and stopped using IPT), 13 lost to follow up, 1 death, 6
side effects, 3 transfer out, 2 pregnancy and 1 active TB
(Fig. 1). All the 6 cases who did not complete 6 months
of IPT due to side effects stopped using IPT on their
own against physicians’ advice. The side effects were
mild rash in 4 patients, burning sensation of limbs in 1
patient and numbness of the feet in 1 patient.
Females were the majority, constituting 77.5 % (994/
1283) of the patients. The majority of the patients (71.6 %)
were aged 30–49 years old. There were 51 (4.0 %) minors
(aged less than 18 years). The mean (± SD) age of all
patients was 39.37 (±10.51). Self-employed patients were
the majority (745/1283, 58.1 %) as were patients who
attained only primary level education (289/1283, 69.5 %).
The vast majority of patients were of low to medium
socio-economic status (1218/1283, 94.9 %). More than half
(55.2 %) of patients had lived with HIV infection for 13–
60 months since diagnosis (598/1283). A total of 655/1283
(52.9 %) had current CD4+ cell counts > 350 cells/μl. More
than two thirds of the patients (76.5 %) were on antiretro-
viral treatment (982/1283). A total of 494/920 (53.7 %) of
those on antiretroviral treatment had been on ARV therapy
for 13–60 months. See Table 1.
One patient withdrew consent after receiving the 1st
monthly dose of INH and had not used the drugs as was
noted in the 2nd month of follow up. This patient was
excluded from the analysis of IPT adherence leaving
1282 patients in this cohort. The overall mean (±SD) for
IPT adherence was 98.9 (±2.9), a strikingly high percentage.
The IPT adherence level among children aged <18 years
(92.2 %) was significantly lower than adherence level among
patients aged 18–29 years (98.3), 30–49 years (98.8) and
those 50 years or older (98.5 %) with a p-value = 0.011. Sex,
occupation, level of education, socio-economic status, HIV
duration since diagnosis, ARV use status, duration of ARV
use and current CD4 counts were not associated with
adherence. See Table 2.
Table 3 presents socio-demographic and clinical charac-
teristics of 6 month IPT non-completers. Non-completers
were exclusively adults aged 18 years or older; however
this was not statistically significant. Adults younger
than 30 years were more likely to be non-completers
than other adult age groups but this was not statisti-
cally significant.
Discussion
The level of acceptance and completion rate of IPT has
been found to be very high in the present study. The
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Fig. 1 Patient recruitment and retention flow chart
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level of acceptance and completion were 99 and 87 %
respectively in another study done in the city of Dar es
Salaam by Munseri et al., 2008 [7]. The high acceptability
of IPT in the two studies indicates that HIV infected
patients are ready to accept interventions that are said
to improve their health. A study in Rio de Janeiro, Brazil
found significantly higher completion rate among patients
already on ARV than those not on ARV [19]. A prior
study in Ethiopia found that individuals who received
pre-treatment counseling from health care workers were
8 times more likely to be adherent to IPT [10]. The
participants of the present study did not receive any
counselling before initiation of IPT.
In the present study the non-completion rate was very
low at 2.2 %. This rate is comparable to the rate in the
Thailand study that found non-TST screened patients
had a dropout rate at 1.7 % compared to 6.3 % in TST
screened subjects (8). However, this rate is substantially
lower than the non-completion rate of 13 % noted by
Munseri et al., in Tanzania [7]. ARV use in Tanzania
10 years ago was substantially less than during the
current study period due to the increased availability
of medications.
The low non-completion rate we found can partly be
explained by the high percentage of anti-retroviral drug
treatment in our study group. Patients had an incentive
to come to the clinic monthly already that was inde-
pendent of IPT therapy thus removing any additional
travel and time burden related to acquiring monthly IPT
medication. A retrospective study in Uganda found an
IPT non-completion rate of 58.1 % among HIV infected
patients seen every other month in 2 non-governmental
organization voluntary counselling and testing clinics
who provided IPT in the form of 300 mg of INH daily
for 9 months [14].
In the present study, non-completers were exclusively
adults aged 18 years or older. The 18–29 year old age
group had the highest rate for non-completion. Special
interventions may need to be devised to retain them in
IPT treatment. Patients with a high socioeconomic sta-
tus showed a higher percentage of non-completers than
other SES categories, however this was not statistically
significant. Mindachew M et al., 2011 could not find the
association between monthly income and IPT adherence
in Ethiopia [10]. The percentages of non-completers did
not differ across other clinical characteristics. Adults of
18 years or older were also found to be the majority of
non-completers in the study in the New York City among
patients attending outpatient chest clinics [6]. This finding
remains unexplained.
Generally, adherence to treatment was very good. Good
adherence might have been a result of patients acting in
the accordance to the directives to take INH daily. The
high adherence level promises good outcomes once IPT
provision becomes a country-wide recommendation in
Tanzania. However, in the present study participants with
a known history of treatment non-compliance were ex-
cluded, possibly creating a selection bias which favored
high adherence.
Adults were significantly more adherent to IPT than
were children. In Tanzania, children 10 years or older are
Table 1 Characteristics of the study participants, N = 1283
Characteristic Number Percentage
Sex: Females 994 77.5
Males 289 22.5
Age groups (in years)




Education (aN = 416)
No formal education 22 5.2.
Primary education 289 69.5









HIV duration in months (bN = 1084)
0-12 241 22.2
13-60 598 55.2




Duration of ARV use in months (cN = 920)
0-12 229 24.9
13-60 494 53.7
> 60 197 21.4
Current CD4 counts in cells/ μl (dN = 1239)
0-200 245 19.8
201-350 339 27.4
> 350 655 52.9
aLevel of education was available for only 416 patients
bOnly 1084 patients had known duration of HIV infection since diagnosis
cOnly 920 of 982 patients on ARVs could recall the date they
commenced ARVs
dOnly 1239 patients had their current CD4 available
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usually informed about their HIV status and trained to be
independent of their guardians when it comes to HIV care
and treatment. A number of children less than 18 years
are already taking their ARVs independently. A study in
Botswana found that compared to controls, non-adherent
cases were more likely to be young [20]. Although chil-
dren were less adherent than adults in the present study,
all the children completed the 6 months of treatment. This
may suggest that children are likely to use TB preventive
therapy correctly when well supervised.
Conclusion
IPT is highly accepted by HIV infected patients. Patients
demonstrated a high level of adherence to IPT therapy.
The level of adherence among children was slightly lower
than that among adults. The high acceptability and
Table 2 Factors associated with adherence to IPT, Na = 1282
Characteristic Total Adherent patients P- value
Number (%)
Sex: Males 289 284 (98.3 %)
Females 993 975 (98.2) 0.926
Age in years
<18 51 47 (92.2)
18-29 120 118 (98.3)
30-49 917 903 (98.5)
≥50 194 191 (98.5) 0.011
Education (aN = 415)
No formal education 22 22 (100)
Primary education 289 285 (98.6)
Secondary/post-secondary education 104 102 (98.1) 0.780
Occupation
Unemployed 398 388 (97.5)
Employed 140 136 (97.1)
Self employed 744 735 (98.8) 0.173
Socio-economic status
Low 520 509 (97.7)
Medium 697 688 (98.7)
High 65 63 (96.9) 0.489
HIV duration since diagnosis (months) (bN = 1084)
0-12 241 235 (97.9)
13-60 598 588 (98.3)
>60 245 239 (97.6) 0.746
ARV use
Yes 981 964 (98.3)
No 301 295 (98.0) 0.766
ARV duration in months (aN = 919)
0-12 229 224 (97.8)
13-60 494 489 (99.0)
>60 196 191 (97.4) 0.266
Current CD4 counts in cells/ μl (aN = 1238)
0-200 245 241 (98.4)
201-350 339 334 (98.5)
>350 654 642 (98.5) 0.914
aOne patient was not analyzed for adherence
bOnly 1084 patients had known duration of HIV infection since diagnosis
**p-value for trend
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adherence levels make a compelling case that HIV in-
fected patients are ready to accept and adhere to IPT.
Adults, especially those aged less than 30 years were
more likely to be IPT non-completers than were children.
Children’s adherence to IPT was acceptably high, however
children might need adult supervision on taking IPT to
obtain as high an adherence rate as the adults.
Study limitation
ARV naïve patients were requested to come to the clinic
on a monthly basis for clinical evaluation and INH refill
despite the fact that some of them had their normal clin-
ical attendance 2 monthly. This could have contributed to
indifference in adherence level between ARV naïve and
ARV-experienced patients.
Table 3 Socio-demographic and clinical characteristics of non-completers
Characteristic Total Non- completers P-value
Number (%)
Sex: Females 994 24 (2.4)
Males 289 4 (1.4) 0.291
Age groups (in years)
< 18 51 0 (0)
18-29 120 6 (5.0)
30-49 917 19 (2.1)
≥ 50 194 3 (1.5) 0.111
Occupation
Unemployed 398 9 (2.3)
Employed 140 3 (2.1)
Self employed 745 16 (2.1) 0.992
Education (N = 416)
No formal education 22 0 (0)
Primary education 289 8 (2.8)
Secondary/post-secondary education 105 5 (4.8) 0.415
Socio-economic status
Low 521 15 (2.9)
Medium 697 10 (1.4)
High 65 3 (4.6) 0.09
HIV duration in months (Na = 1084)
0-12 241 7 (2.9)
13-60 598 9 (1.5)
> 60 245 7 (2.9) 0.295
ARV use
Yes 982 20 (2.0)
No 301 8 (2.7) 0.519
Duration of ARV use in months (Nb = 920)
0-12 229 5 (2.2)
13-60 494 9 (1.8)
> 60 197 5 (2.5) 0.828
Current CD4 counts in cells/μl (Nc = 1238)
0-200 245 7 (2.9)
201-350 339 6 (1.8)
> 350 655 15 (2.3) 0.682
aOnly 1084 patients had known duration of HIV infection since diagnosis
bOnly 920 of 982 patients on ARVs could recall the date they commenced ARVs
cOne patient was not analyzed for adherence
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